BET Bromodomain Inhibitors as an Emerging Class of Anticancer Agents
Author:
Publisher
Springer International Publishing
Link
https://link.springer.com/content/pdf/10.1007/978-3-030-80962-1_401-1
Reference107 articles.
1. Aguirre-Portolés C, Feliu J, Reglero G, Ramírez de Molina A (2018) ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin-1-dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone. Mol Oncol 12(10):1735–1752
2. Alqahtani A, Choucair K, Ashraf M, Hammouda DM, Alloghbi A, Khan T et al (2019) Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA 5(3):FSO372
3. Andrews FH, Singh AR, Joshi S, Smith CA, Morales GA, Garlich JR et al (2017) Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc Natl Acad Sci U S A 114(7):E1072-e80
4. Aylott HE, Atkinson SJ, Bamborough P, Bassil A, Chung C-w, Gordon L et al (2021) Template-hopping approach leads to potent, selective, and highly soluble bromo and extraterminal domain (BET) second bromodomain (BRD2) inhibitors. J Med Chem 64(6):3249–3281
5. Bharatham N, Slavish PJ, Shadrick WR, Young BM, Shelat AA (2018) The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors. J Mol Graph Model 81:197–210
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3